Highlights Symrise AG

Equities

SY1

DE000SYM9999

Specialty Chemicals

Market Closed - Xetra Other stock markets 16:39:33 15/05/2026 BST			5-day change	1st Jan Change
73.76 ^EUR	-0.78%		+0.68%	+7.08%

05-12	SYMRISE AG : Buy rating from DZ Bank	ZD
05-12	SYMRISE AG : JP Morgan gives a Buy rating	ZD

Highlights

05-06	For final dividend	FA
04-30	Symrise Maintained at Buy as Mwb Notes 'Better-than-feared' Q1 Results	MT
04-29	Symrise: Q1 lifts the floor, guidance intact
04-29	Germany's Symrise narrowly beats sales expectations on higher pricing	RE
04-29	Symrise reports Q1 sales of around EUR 1.25 bln	RE
04-29	Germany's Symrise narrowly beats sales expectations on higher pricing	RE
03-25	AlphaValue/Baader Europe Adjusts Forecasts for Symrise After FY25 Results	MT
03-04	Symrise AG announces Annual dividend, payable on May 11, 2026	CI
03-04	Symrise AG Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-04	Symrise: Strong base entering 2026, volume to drive the next leg
03-04	Symrise Raises Dividend Again Despite Write-Downs Weighing on Results	RE
03-04	Symrise posts 2.8% organic sales growth in 2025 and higher margins	RE
03-04	Symrise organic sales growth of 2.8%, sales at 4.93 billion EUR versus consensus 4.93 billion	RE
02-09	Symrise AG commences an Equity Buyback Plan for 13,977,205 shares, representing 10% of its issued share capital, under the authorization approved on May 20, 2025.	CI
02-09	US Drops Antitrust Investigation Against Symrise	RE
02-09	Symrise says U.S. Department Of Justice drops antitrust probe	RE
02-09	Symrise confirms investigations against Symrise in antitrust proceedings by U.S. Department of Justice discontinued	RE
02-06	Berenberg Revises Symrise Price Target, Estimates Amid Sustained Soft End-market Projections	MT
01-13	Symrise Continues Recovery Thanks to Business Sale and Share Buybacks	DP
01-13	Symrise Accelerates Recovery – Terpene Sale and Share Buybacks	DP
01-13	Symrise Misses Forecast and Plans Share Buyback	RE
01-12	Symrise announces buyback amid advanced talks to sell terpenes unit	AN
01-12	Germany's Symrise says potential unit sale, Swedencare impairment to hurt earnings	RE
01-12	Symrise AG resolves a share buy-back program in the amount of EUR 400 million	RE
01-12	Germany's Symrise to sell terpenes business, take $169 million impairment charge	RE